Funding for this research was provided by:
Merck & Co., Inc. | Merck Sharp and Dohme (n/a)
Received: 25 November 2020
Accepted: 29 March 2021
First Online: 28 April 2021
: Vamsidhar Velcheti has served in an advisory and/or consultant role for Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, Celgene, Novartis, Amgen, Fulgent Genetics, Reddy Labs, Alkermes, Nektar Therapeutics, and Foundation Medicine. Xiaohan Hu, Bilal Piperdi, and Thomas Burke are full-time employees of Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and own stock of Merck & Co., Inc., Kenilworth, NJ, USA.